about the company

Firebrick Pharma

Firebrick Pharma has developed an anti-viral nasal spray that could be an effective treatment for symptoms of the common cold.

Firebrick Pharma Pty Ltd is an Australian private company, founded in 2012 by two experienced pharmaceutical and biotech executives.

Drawing on their expertise in drug development and respiratory viral diseases, their vision was to create a treatment for the common cold using an entirely innovative approach.

They succeeded, and Firebrick is currently completing the final clinical trials to have their patented nasal spray product approved for sale.


In treating colds, the challenge has always been that the infection of the nasal passages can be caused by any one of 200 viruses from at least six major groups.

The problem is that we rarely know the culprit and they often mutate, making a vaccine or targeted drug therapy impossible; that’s why no one has been able to develop a vaccine or anti-viral drug for colds.

At Firebrick, we took an innovative approach, using a unique chemical agent which has been shown to kill virtually all the known viruses that can cause colds, and yet is safe for use in the nose. What’s more, because of the indiscriminate way it kills viruses, there has never been a report of viral resistance to the agent.

The Firebrick anti-viral nasal spray is designed to rapidly degrade the virus population in the nasal passages and interrupt the infection cycle, potentially reducing the severity of cold symptoms.

Breakthrough-2 (1)


  • 2012

    Firebrick Pharma Pty Ltd incorporated by Peter Molloy and Stephen Goodall with the mission to create a microbicidal nasal spray to treat the common cold.

  • 2013

    Product development commences.

  • 2014

    Australian patent filed.

  • 2015

    Australian patent granted and international patent filings commence. Formulation development commences in Melbourne laboratories.

  • 2016

    Series A funding closes; product development accelerates.

  • 2017

    Product formulation, packaging and manufacturing development completed; viral inactivation studies confirm activity.

  • 2018

    Safety testing models indicate product is safe for nasal use; new patents filed; Series B funding closes. Phase 1 and Phase 2 trials completed.

  • 2019

    Series C funding and pivotal clinical trial commencing.

Firebrick Pharma Team

Peter L Molloy

Chairman & Founder, BSc, MBA, FAICD

Peter Molloy trained as a microbiologist and biochemist and subsequently built a successful career in the international pharmaceutical industry. At Pharmacia (Pfizer) he was Managing Director of Australia/NZ operations and later Vice President for Strategic Marketing, responsible for the marketing of hundreds of pharmaceuticals across 22 countries. During his pharmaceutical career, he has directly launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals. Subsequently, as CEO of four biotech companies, he has led numerous R&D programs, moved several drugs from research into human clinical trials, and executed valuable international pharmaceutical partnerships including two $100m+ licensing deals. In 2002-2005, he was CEO of one of the world's leading antiviral research companies, Biota Holdings Limited, where during his term the company’s market value increased from $30m to around $300m. He has extensive knowledge and expertise in the development and marketing of oral and topical antimicrobial agents, and at Biota managed R&D programs focused on new drug treatments for respiratory viral diseases.

SFG photo

Stephen Goodall

COO & Co-founder, BAppSc, MAppSc, MBA, PhD

Stephen Goodall has a successful track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was Chief Operating Officer of Viralytics, which was successfully acquired in 2018 for $500 million by the US big pharma company, Merck. Previously, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical for 11 years. He has extensive experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has an impressive background in process development, production scale-up and GMP manufacturing for pharmaceuticals.


Linda Friedland

Head of Business Development, MD

Dr Linda Friedland is the Company’s Head of Business Development (appointed January 2019). Based in Perth, WA, Dr Friedland is a physician with over 20 years’ experience in clinical medicine (oncology, microbiology, renal medicine and women’s health) combined with strategy and governance expertise and global connections. She consults internationally to healthcare, biotech, corporate and financial institutions. In addition to her Firebrick Pharma role, Dr Friedland is the Chief Scientific Officer for Wayal Health Sciences Inc (USA), Senior Consultant to TargImmune Therapeutics (Basel, Switzerland), clinical and scientific advisor to Shanghai-based Joint US China Clean Energy Commission (JUCCE) and a director on the board of the Neurology Council of Western Australia. She has developed and implemented numerous public health and disease management programs throughout Asia, USA, Australia, Africa and the UK, where she continues to travel and lecture. An author of seven health and medical bestsellers, with a long career in television, radio and medical communications, Linda is a highly regarded international keynote speaker, director and a Graduate of the Australian Institute of Company Directors (GAICD).


Peter Kash

Business Advisor, BS, MBA, EdD

Dr Peter Kash is the Company’s global Business Advisor (appointed January 2019). Based in New York, Peter Kash worked on Wall Street for 30 years and is a renowned biotech entrepreneur, who has raised at least US$1 billion for private biotech companies and co-founded more than a dozen companies, which collectively have six FDA-approved drugs. Dr Kash holds a BSc in Management Science, an MBA in Banking and International Finance and a Doctorate in Education. He has held professorships at leading universities, including the Wharton School of Business. He has held Adjunct, Associate and Visiting professorships at leading universities, including the Wharton School of Business. He has authored or co-authored several books, with one being an international bestseller. These include, Make Your Own Luck, Take Two Tablets: Medicine from the Bible, and most recently, Freedom From Disease.


Professor Peter Friedland

Chief Medical Officer, MBBCh MMed FRACS FCS (SA)

Professor Peter Friedland is the Company’s Chief Medical Officer (appointed March 2019). Prof Friedland is an ENT (ear, nose and throat) specialist and associate professor at the University of Western Australia and professor at the University of Notre Dame, Fremantle. He holds several national appointments including board member of the Australian Society of Otorhinolaryngology Head & Neck Surgery at Royal Australian College of Surgeons (RACS), member of the Panel of Clinical Experts for the Australian Government Department of Health and member of MBS (Medical Benefit Schemes) National ENT Taskforce. Prof Friedland, a surgeon scientist at Sir Charles Gairdner hospital, is currently involved in multidisciplinary clinical research in all aspects of ENT and head and neck cancer. Over the last 10 years, he has published more than 40 peer reviewed scientific articles and delivered over 150 conference presentations and invited lectures. In his teaching and training role, he is Chair of the RACS WA ENT Training Scheme and the recipient of nine prestigious national and university teaching awards. Prof Friedland travels regularly to conduct clinics and surgery in remote locations such as the Kimberley and Pilbara regions of WA. From 2005 to 2009, he was clinical head of the ENT department at the University of Witwatersrand, Johannesburg where he convened the first cochlear implant workshop in Africa. In addition, he committed himself to regular consulting in pro bono outreach ENT programs in the underprivileged and rural areas in Southern Africa. Prof Friedland was privileged to be Mr Nelson Mandela’s ENT from 2000 to 2009 before immigrating to Perth with his family.